Olkem-Beta 25mg 10 Tablets

babies: it does not apply to babies. lactating mother: olmesartan medoxomil and metoprolol succinate tablets are safe to use during breastfeeding.
limited human studies have shown that this drug may not pass into breast milk and does not harm the baby. alcohol: it is unsafe to consume alcohol with olmesartan medoxomil, metoprolol succinate tablet.
driving: this medication may cause dizziness, and it reduces your alertness. do not drive if these symptoms occur.
kidney: it should be used with caution in patients with severe kidney disease. dose adjustment is required.
consult your doctor. liver: olmesartan medoxomil, metoprolol succinate tablet should be used with caution in patients with liver disease.
dose adjustment is required. consult your doctor..

Nausea Diarrhea Constipation Weakness Dizziness Cold extremities Numbness of extremity Increased potassium level in the body Slow heart rate Decreased blood pressure.

OLKEM BETA is an angiotensin receptor blocker (arb). it works by blocking the hormone angiotensin, thus relaxing blood vessels.
metoprolol is a beta-blocker. it works on the heart and reduces the heart rate, thus decreases blood pressure.
hence allows the blood to flow smoothly and the heart to pump more efficiently..

If you miss a dose of OLKEM BETA, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• OLKEM BETA tablet is used to treat high blood pressure • this medication may dizziness, do not drive, or get up slowly from a sitting or lying position • medication should not be stopped unless told by your doctor • this medication prevents heart attack and stroke by reducing blood pressure.

• olmesartan medoxomil + benazepril: concurrent use may result in an increased risk of adverse events like hypotension, syncope, hyperkalemia, and acute renal failure. • olmesartan medoxomil + perindopril: concurrent use may result in an increased risk of adverse events like hypotension, syncope, hyperkalemia, and acute renal failure. • olmesartan medoxomil + bromfenac: concurrent use may result in renal dysfunction and/or increased blood pressure. • olmesartan medoxomil + diclofenac: concurrent use may result in renal dysfunction and/or increased blood pressure. • metoprolol succinate + albuterol: concurrent use may result in decreased efficacy of albuterol. • metoprolol succinate + crizotinib: concurrent use may result in an increased risk of bradycardia. • metoprolol succinate + fenoldopam: concurrent use may result in exaggeration of hypotensive response. • metoprolol succinate + acarbose: concurrent use may result in hypoglycemia or hyperglycemia. • metoprolol succinate + clonixin: concurrent use may result in increased blood pressure..